The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE）

Summary

This is a multicenter, double-blind, randomized, placebo-controlled phase Ⅱ study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of YN-011 in subjects with overweight (27 kg/m2 ≤ BMI \< 30 kg/m2, with at least one comorbidity) or obesity (BMI ≥ 30 kg/m2, with or without comorbidities). The entire study period will consist of a 2-week screening period, a 22-week double-blind treatment period, and a 4-week off-treatment follow-up period

Timeline

Start

2025-08-25

Primary completion

2026-06-01

Completion

2026-08-01

Drugs

Indications